HCV genotypes and their determinative role in hepatitis C treatment

被引：40
作者：
Keikha M. [1 ]
Eslami M. [2 ]
Yousefi B. [3 ]
Ali-Hassanzadeh M. [4 ]
Kamali A. [5 ]
Yousefi M. [1 ]
Karbalaei M. [6 ]
机构：
[1] Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad
[2] Cancer Research Center, Semnan University of Medical Sciences, Semnan
[3] Department of Immunology, Semnan University of Medical Sciences, Semnan
[4] Department of Immunology, School of Medicine, Jiroft University of Medical Sciences, Jiroft
[5] Department of Internal Medicine, School of Medicine, Jiroft University of Medical Sciences, Jiroft
[6] Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft
来源：
VirusDisease | 2020年 / 31卷 / 3期
关键词：
Antiviral agent; Hepatitis C virus; Hepatitis virus; Interferon;
D O I：
10.1007/s13337-020-00592-0
中图分类号：
学科分类号：
摘要：
Nowadays, exposure to infectious diseases caused by pathogenic viruses has become one of the major human concerns in health fields. In the meantime, hepatitis viruses are associated with health problems, especially in liver tissue. So far, several types of these viruses have been known including: HAV, HBV, HCV, HDV, HEV, and HGV. Nevertheless, it seems that hepatitis C is the major viral infection among all of the hepatitis infections. The cirrhosis and hepatocellular carcinoma are known as the most important pathological complications of this virus, from which seven genotypes have been identified. However, among these genotypes, the incidence rate of genotypes 1 and 3 is more than others. In this review, we have investigated the relationship between all HCV genotypes and therapeutic responses against them. Regarding heterogeneity between hepatitis C genotypes, it is not possible to access an effective vaccine against this virus, and treatment is the only applicable strategy. Response to treatment is different among genotypes, and it has resulted that each genotype has a specific therapeutic regimen of itself. Therefore, it seems that determination of hepatitis C genotype, as a key tool, is essential in controlling therapeutic regimen, improving local control programs and eventually producing an effective vaccine. © 2020, Indian Virological Society.
引用
收藏
页码：235 / 240
页数：5
相关论文
共 48 条
  • [1] Ahmed M., Era of direct acting anti-viral agents for the treatment of hepatitis C, World J Hepatol, 10, 10, (2018)
  • [2] Ahmed H., Et al., Meta-analysis of grazoprevir plus elbasvir for treatment of hepatitis C virus genotype 1 infection, Ann Hepatol, 17, 1, pp. 18-32, (2018)
  • [3] Ahmed O.A., Et al., Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village, Int J Hepatol, 2018, (2018)
  • [4] Al Naamani K., Al Sinani S., Deschenes M., Epidemiology and treatment of hepatitis C genotypes 5 and 6, Can J Gastroenterol Hepatol, 27, 1, pp. e8-e12, (2013)
  • [5] Asselah T., Et al., Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis, Clin Gastroenterol Hepatol, 16, 3, pp. 417-426, (2018)
  • [6] Cariani E., Et al., Translating pharmacogenetics into clinical practice: interleukin (IL) 28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection, Clin Chem Lab Med, 49, 8, pp. 1247-1256, (2011)
  • [7] Cartwright E.J., Miller L., Novel drugs in the management of difficult-to-treat hepatitis C genotypes, Hepat Med, 5, (2013)
  • [8] Chen T.-Y., Et al., Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection, Transl Res, 150, 2, pp. 116-121, (2007)
  • [9] Chung R.T., Et al., Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection, Clin Infect Dis, 67, 10, pp. 1477-1492, (2018)
  • [10] Cohen D.E., Clinical development of Viekira Pak to Mavyret, HCV: the journey from discovery to a cure. Topics in medicinal chemistry, 32, (2019)
12345